Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 7 · below the Ichimoku cloud · RSI 35 · MACD below its signal · 5% above its 52-week low
None of the 29 investors followed here reported a position in 9995.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 9995.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 26, 2026 | Wang (Yuxiao)Director (Executive) | Sale at price 10.40 per share. | 13.5K | $140.42K |
| Aug 25, 2026 | Wang (Yuxiao)Director (Executive) | Sale at price 10.46 per share. | 6.5K | $67.99K |
| Jul 21, 2026 | Wang (Liqiang)Director (Non-Executive) | Sale at price 11.29 per share. | 20K | $225.72K |
| Jun 8, 2026 | Lin (Jian)Director (Executive) | — | 8.9K | — |
| Jun 8, 2026 | Wang (Liqiang)Director (Non-Executive) | — | 60.9K | — |
| Jun 8, 2026 | Wang (Weidong)Chairman of the Board | — | 350K | — |
| Jun 8, 2026 | Wen (Qingkai)Director (Executive) | — | 50.9K | — |
| Mar 30, 2026 | Wang (Weidong)Chairman of the Board | Sale at price 12.25 per share. | 186K | $2.28M |
| Jan 22, 2026 | Wang (Weidong)Chairman of the Board | Sale at price 11.79 per share. | 53K | $625.07K |
| Jan 21, 2026 | Fang (Jianmin)Chief Executive Officer | Sale at price 11.78 per share. | 2.50M | $29.46M |
| Jan 20, 2026 | Wang (Weidong)Chairman of the Board | Sale at price 12.33 per share. | 47.5K | $585.74K |
| Jan 15, 2026 | Wang (Weidong)Chairman of the Board | Sale at price 12.47 per share. | 20K | $249.36K |
| Jan 13, 2026 | Wang (Weidong)Chairman of the Board | — | 212.5K | — |
| Jan 12, 2026 | Wang (Weidong)Chairman of the Board | Sale at price 13.20 per share. | 60K | $792.26K |
| Dec 4, 2025 | Wang (Weidong)Chairman of the Board | Sale at price 11.57 per share. | 10K | $115.70K |
| Nov 26, 2025 | Wang (Weidong)Chairman of the Board | Sale at price 11.47 per share. | 160K | $1.84M |
| Nov 25, 2025 | Wang (Weidong)Chairman of the Board | Sale at price 11.06 per share. | 60K | $663.38K |
| Nov 23, 2025 | Wang (Weidong)Chairman of the Board | Sale at price 10.92 per share. | 60K | $655.42K |
| Sep 29, 2025 | Wang (Weidong)Chairman of the Board | Sale at price 15.42 per share. | 20K | $308.38K |
| Sep 28, 2025 | Wang (Weidong)Chairman of the Board | Sale at price 13.94 per share. | 100K | $1.39M |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 17.2 | -4.3 | 18.9 | 5.0 | -17.8 | -10.1 | 10.0 | -1.3 | -4.5 | -13.6 | −7.2% | ||
| 2025 | -7.4 | 35.8 | 31.8 | 60.5 | 26.7 | 13.0 | 10.7 | 62.8 | 19.4 | -23.2 | 3.3 | -22.7 | +402.4% |
| 2024 | -59.4 | 47.8 | 20.7 | 2.9 | -9.3 | -3.4 | -41.8 | -12.6 | 37.2 | -1.5 | 5.5 | -19.5 | −61.8% |
| 2023 | 8.8 | -18.4 | -18.6 | 9.4 | -26.1 | 1.2 | 28.9 | -17.1 | 10.1 | 10.5 | 1.3 | -17.1 | −35.3% |
| 2022 | -34.0 | 31.0 | -30.9 | -27.3 | -11.5 | 47.0 | 2.2 | 0.0 | -15.3 | 29.8 | 0.1 | 17.1 | −25.5% |
| 2021 | 9.9 | 8.3 | -14.5 | 6.5 | 8.6 | 6.1 | -16.2 | 1.3 | -1.9 | -1.7 | 9.2 | -26.5 | −18.0% |
| 2020 | 35.4 | +35.4% |
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Buy / hold / sell counts
No recent headlines.